Cargando…

The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes

Inherited defects of the neuromuscular junction (NMJ) comprise an increasingly diverse range of disorders, termed congenital myasthenic syndromes (CMS). Therapies acting on the sympathetic nervous system, including the selective β2 adrenergic agonist salbutamol and the α and β adrenergic agonist eph...

Descripción completa

Detalles Bibliográficos
Autores principales:	McMacken, Grace, Cox, Dan, Roos, Andreas, Müller, Juliane, Whittaker, Roger, Lochmüller, Hanns
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905648/ https://www.ncbi.nlm.nih.gov/pubmed/29462491 http://dx.doi.org/10.1093/hmg/ddy062

Ejemplares similares

Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome
por: McMacken, Grace M, et al.
Publicado: (2019)

Neuromuscular junction involvement in inherited motor neuropathies: genetic heterogeneity and effect of oral salbutamol treatment
por: McMacken, Grace, et al.
Publicado: (2023)

Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome
por: Spendiff, Sally, et al.
Publicado: (2020)

Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients
por: McMacken, Grace, et al.
Publicado: (2017)

Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK
por: Gallenmüller, Constanze, et al.
Publicado: (2014)

Mitochondrial Mutations Can Alter Neuromuscular Transmission in Congenital Myasthenic Syndrome and Mitochondrial Disease
por: O’Connor, Kaela, et al.
Publicado: (2023)

Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions
por: Nicole, Sophie, et al.
Publicado: (2017)

The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes
por: Rodríguez Cruz, Pedro M., et al.
Publicado: (2018)

The role of Rapsyn in neuromuscular junction and congenital myasthenic syndrome
por: Liao, Xufeng, et al.
Publicado: (2023)

Acute therapy for hyperkalemia with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients.
por: Kim, H. J.
Publicado: (1997)

Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness
por: Evangelista, Teresinha, et al.
Publicado: (2015)

Beta-Adrenergic Agonists
por: Barisione, Giovanni, et al.
Publicado: (2010)

Editorial: Molecular Mechanisms Underlying Assembly and Maintenance of the Neuromuscular Junction
por: Herbst, Ruth, et al.
Publicado: (2021)

Stimulation of the beta-2-adrenergic receptor with salbutamol activates human brown adipose tissue
por: Straat, Maaike E., et al.
Publicado: (2023)

Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant
por: Balaraju, Sunitha, et al.
Publicado: (2019)

Behr syndrome and hypertrophic cardiomyopathy in a family with a novel UCHL1 deletion
por: McMacken, Grace, et al.
Publicado: (2020)

Identification of mutations in the MYO9A gene in patients with congenital myasthenic syndrome
por: O’Connor, Emily, et al.
Publicado: (2016)

Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders
por: Clausen, Lisa, et al.
Publicado: (2018)

Neuromuscular Junction Changes in a Mouse Model of Charcot-Marie-Tooth Disease Type 4C
por: Cipriani, Silvia, et al.
Publicado: (2018)

β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure
por: Vanhaesebrouck, An E, et al.
Publicado: (2019)

Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome
por: Thompson, Rachel, et al.
Publicado: (2019)

Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia
por: Webster, Richard G, et al.
Publicado: (2020)

Intragenic DOK7 deletion detected by whole-genome sequencing in congenital myasthenic syndromes
por: Azuma, Yoshiteru, et al.
Publicado: (2017)

Presynaptic Congenital Myasthenic Syndromes: Understanding Clinical Phenotypes through In vivo Models
por: Pugliese, Alessia, et al.
Publicado: (2023)

Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes—A Retrospective Single Centre Cohort Study
por: Della Marina, Adela, et al.
Publicado: (2020)

Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes
por: Webster, Richard G.
Publicado: (2018)

A multi-source approach to determine SMA incidence and research ready population
por: Verhaart, Ingrid E. C., et al.
Publicado: (2017)

Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes
por: Petrov, Konstantin A., et al.
Publicado: (2018)

Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies
por: Belaya, Katsiaryna, et al.
Publicado: (2015)

A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
por: Thompson, Rachel, et al.
Publicado: (2018)

Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
por: Haney, Sarah, et al.
Publicado: (2007)

Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury
por: Manocha, Sanjay, et al.
Publicado: (2006)

The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro
por: Anderson, Ronald, et al.
Publicado: (2014)

MYO9A deficiency in motor neurons is associated with reduced neuromuscular agrin secretion
por: O’Connor, Emily, et al.
Publicado: (2018)

Agonist-induced myopathy at the neuromuscular junction is mediated by calcium
Publicado: (1979)

Global N-linked Glycosylation is Not Significantly Impaired in Myoblasts in Congenital Myasthenic Syndromes Caused by Defective Glutamine-Fructose-6-Phosphate Transaminase 1 (GFPT1)
por: Chen, Qiushi, et al.
Publicado: (2015)

Zebrafish mutants of the neuromuscular junction: swimming in the gene pool
por: Daikoku, Eriko, et al.
Publicado: (2015)

MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide
por: Reza, Mojgan, et al.
Publicado: (2017)

Effect of beta-adrenergic agonist on alveolar fluid clearance in rats
por: Qiu, H, et al.
Publicado: (2005)

Differential Modulation of Beta-Adrenergic Receptor Signaling by Trace Amine-Associated Receptor 1 Agonists
por: Kleinau, Gunnar, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6nnskvso4ic1bndhbg8irtn8jj